Propel Bio Management, LLC / NKTR
Propel Bio Management, LLC’s Nektar Therapeutics Position
Does Propel Bio Management, LLC own Nektar Therapeutics (NKTR)? Not currently — the last reported position was 82.8K shares worth $4M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$4M
Q4 2025
Shares
82.8K
% of Portfolio
+2.99%
Quarters Held
2
position exited
Position History NKTR
Reported value by quarter
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of NKTR.